Evidence map›Paper›PMID 42013844›Full record

ArticleCell reports. Medicine2026

Metabolic reprogramming of the infant gut by bifidobacteria-based probiotics drives exclusion of antibiotic-resistant pathobionts.

Ahmed Bargheet, Gaute Hovde Bø, Marit Andrea Klokkhammer Hetland, Museveni Justine, Sabrina John Moyo, Iren Høyland Löhr, Bjørn Blomberg, Nina Langeland, Claus Klingenberg, Veronika Kuchařová Pettersen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Microorganisms · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ahmed BargheetHost-Microbe Interaction Research Group, Department of Medical Biology, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway; Research Group for Child and Adolescent Health, Department of Clinical Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway; Center for New Antibacterial Strategies, UiT The Arctic University of Norway, Tromsø, Norway.
Gaute Hovde BøHost-Microbe Interaction Research Group, Department of Medical Biology, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway; Research Group for Child and Adolescent Health, Department of Clinical Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway; Center for New Antibacterial Strategies, UiT The Arctic University of Norway, Tromsø, Norway.
Marit Andrea Klokkhammer HetlandDepartment of Medical Microbiology, Stavanger University Hospital, Stavanger, Norway; Department of Biological Sciences, Faculty of Science and Technology, University of Bergen, Bergen, Norway.
Museveni JustineResearch Group for Child and Adolescent Health, Department of Clinical Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway; Center for New Antibacterial Strategies, UiT The Arctic University of Norway, Tromsø, Norway; Department of Paediatrics, Haydom Lutheran Hospital, Mbulu, Manyara, Tanzania; Haydom Global Health Research Centre, Haydom Lutheran Hospital, Haydom, Tanzania.
Sabrina John MoyoDepartment of Clinical Science, University of Bergen, Bergen, Norway; Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, UK.
Iren Høyland LöhrDepartment of Medical Microbiology, Stavanger University Hospital, Stavanger, Norway; Department of Biological Sciences, Faculty of Science and Technology, University of Bergen, Bergen, Norway.
Bjørn BlombergDepartment of Clinical Science, University of Bergen, Bergen, Norway; National Centre for Tropical Infectious Diseases, Haukeland University Hospital, Bergen, Norway.
Nina LangelandDepartment of Clinical Science, University of Bergen, Bergen, Norway; National Centre for Tropical Infectious Diseases, Haukeland University Hospital, Bergen, Norway; Norwegian Institute of Public Health, Oslo, Norway.
Claus KlingenbergResearch Group for Child and Adolescent Health, Department of Clinical Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway; Department of Pediatrics, University Hospital of North Norway, Tromsø, Norway.
Veronika Kuchařová PettersenHost-Microbe Interaction Research Group, Department of Medical Biology, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway; Research Group for Child and Adolescent Health, Department of Clinical Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway; Center for New Antibacterial Strategies, UiT The Arctic University of Norway, Tromsø, Norway. Electronic address: veronika.k.pettersen@uit.no.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early-life probiotics that strengthen gut resilience in infants are a promising strategy to combat the global emergency of antibiotic resistance. Still, their effects on antibiotic-resistant opportunistic pathogens, i.e., pathobionts, remain unclear. We evaluate the effects of probiotic supplementation in 152 full-term Tanzanian infants enrolled in the ProRIDE trial. Oral probiotics during the first 4 weeks of life increase gut colonization by Bifidobacterium species, while suppressing pathobionts, including extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E). Integrated metagenomics and metabolomics show that probiotics reduce resistome load and mobilome richness at 6 weeks, accompanied by concurrent shifts in the fecal metabolome. Specifically, the intervention increases lactate and pyruvate and reduces cross-feeding pathways that lead to propionate and butyrate, which partly explains the reduction in ESBL-E carriage. Our study documents putative pathways by which probiotic-driven Bifidobacterium colonization modulates the infant gut toward a lower level of antibiotic resistance.

Indexed as

BifidobacteriumDrug Resistance, BacterialDrug Resistance, MicrobialGastrointestinal MicrobiomeProbioticsAnti-Bacterial AgentsFecesFemaleHumansInfantInfant, NewbornMaleMetabolomeAnti-Bacterial Agentsantimicrobial drug resistanceBifidobacteriuminfantmetabolomemicrobiotaprobiotics

Identifiers

PMID42013844
PMCPMC13198307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.